Biotech Values

[DewDiligence]

PFE GLP-1 addendum:

Danuglipron is an oral, non-peptide GLP-1 agonist that is one of two similar oral drugs PFE is evaluating—the other one is PF-07081532 (#msg-170749309). Both compounds can be dosed without regard to food, which PFE sees as a material advantage compared to NVO's Rybelsus, which requires a strict fasting protocol (#msg-171530263).

PFE intends to advance only one of these two similar GLP-1 compounds to phase-3; the determination of which one to advance will be made after the completion of the two phase-2b trials for obese patients now in progress.